Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending

Executive Summary

Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira

You may also be interested in...



Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says

Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16

Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says

Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16

Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small

GlaxoSmithKline's levitating act in the third quarter shows that co-promotion deals have kept their magic for the company

Related Content

UsernamePublicRestriction

Register

PS042376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel